Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1475-2840
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Effects of empagliflozin versus placebo on cardiac sympathetic activity in acute myocardial infarction patients with type 2 diabetes mellitus: the EMBODY trial ; volume:19 ; number:1 ; day:25 ; month:9 ; year:2020 ; pages:1-12 ; date:12.2020
Cardiovascular diabetology ; 19, Heft 1 (25.9.2020), 1-12, 12.2020
- Urheber
-
Shimizu, Wataru
Kubota, Yoshiaki
Hoshika, Yu
Mozawa, Kosuke
Tara, Shuhei
Tokita, Yukichi
Yodogawa, Kenji
Iwasaki, Yu-ki
Yamamoto, Takeshi
Takano, Hitoshi
Tsukada, Yayoi
Asai, Kuniya
Miyamoto, Masaaki
Miyauchi, Yasushi
Kodani, Eitaro
Ishikawa, Masahiro
Maruyama, Mitsunori
Ogano, Michio
Tanabe, Jun
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12933-020-01127-z
- URN
-
urn:nbn:de:101:1-2020111321195755144744
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:37 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Shimizu, Wataru
- Kubota, Yoshiaki
- Hoshika, Yu
- Mozawa, Kosuke
- Tara, Shuhei
- Tokita, Yukichi
- Yodogawa, Kenji
- Iwasaki, Yu-ki
- Yamamoto, Takeshi
- Takano, Hitoshi
- Tsukada, Yayoi
- Asai, Kuniya
- Miyamoto, Masaaki
- Miyauchi, Yasushi
- Kodani, Eitaro
- Ishikawa, Masahiro
- Maruyama, Mitsunori
- Ogano, Michio
- Tanabe, Jun
- SpringerLink (Online service)
Ähnliche Objekte (12)
Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale
Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
Periprocedural Myocardial Infarction
Mechanical circulatory support reduces renal sympathetic nerve activity in an ovine model of acute myocardial infarction
The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
Type II Myocardial Infarction
An unusual myocardial infarction
Pregnancy-related myocardial infarction
Activation of oxytocin neurons in the paraventricular nucleus drives cardiac sympathetic nerve activation following myocardial infarction in rats
Acute effects of empagliflozin on open-loop baroreflex function and urinary glucose excretion in rats with chronic myocardial infarction
Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale
Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
Periprocedural Myocardial Infarction
Mechanical circulatory support reduces renal sympathetic nerve activity in an ovine model of acute myocardial infarction
The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
Type II Myocardial Infarction
An unusual myocardial infarction
Pregnancy-related myocardial infarction
Activation of oxytocin neurons in the paraventricular nucleus drives cardiac sympathetic nerve activation following myocardial infarction in rats
Acute effects of empagliflozin on open-loop baroreflex function and urinary glucose excretion in rats with chronic myocardial infarction
Effect of Empagliflozin Versus Placebo on Cardiac Sympathetic Activity in Acute Myocardial Infarction Patients with Type 2 Diabetes Mellitus: Rationale
Effect of Empagliflozin Versus Placebo on Plasma Volume Status in Patients with Acute Myocardial Infarction and Type 2 Diabetes Mellitus
Empagliflozin prevents doxorubicin-induced myocardial dysfunction
Empagliflozin protects against atherosclerosis progression by modulating lipid profiles and sympathetic activity
Periprocedural Myocardial Infarction
Mechanical circulatory support reduces renal sympathetic nerve activity in an ovine model of acute myocardial infarction
The impact of empagliflozin on cardiac physiology and fibrosis early after myocardial infarction in non-diabetic rats
Type II Myocardial Infarction
An unusual myocardial infarction
Pregnancy-related myocardial infarction
Activation of oxytocin neurons in the paraventricular nucleus drives cardiac sympathetic nerve activation following myocardial infarction in rats